Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants

PURPOSE: BMS-986142 is an oral, small-molecule reversible inhibitor of Bruton’s tyrosine kinase. The main objectives of our phase I studies were to characterize the safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-986142 in healthy participants, and to investigate the potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sun Ku, Xing, Jun, Catlett, Ian M., Adamczyk, Robert, Griffies, Amber, Liu, Ang, Murthy, Bindu, Nowak, Miroslawa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423977/
https://www.ncbi.nlm.nih.gov/pubmed/28265691
http://dx.doi.org/10.1007/s00228-017-2226-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423977/
https://www.ncbi.nlm.nih.gov/pubmed/28265691
http://dx.doi.org/10.1007/s00228-017-2226-2

Ejemplares similares